July 9, 2020 / 1:02 PM / a month ago

BRIEF-Assembly Biosciences Announces FDA Fast Track Designation Granted To Abi-H2158

July 9 (Reuters) - Assembly Biosciences Inc:

* ASSEMBLY BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO ABI-H2158 FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION

* ASSEMBLY BIOSCIENCES - ABI-H2158 IS BEING EVALUATED IN AN ONGOING GLOBAL PHASE 2 TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below